We plan it for an on-coming study. DISCUSSION Our long-term results, comparing to other studies,4,5 show that AS is highly sensitive to platinum-based chemotherapy, with up to 85%–100% of patients

showing durable complete remission1,5 and survival rates greater than 90% in 10 years.1,6 Toxicity was mild and manageable in most of the studies, apart from reports of late second primaries, either solid or hematological in nature7–9 which can be a real challenge in cured patients. Most common acute and chronic side effects of BEP or other platinum-based chemotherapy consist of myelosuppression Inhibitors,research,lifescience,medical of various grades, nephrotoxicity, peripheral neuropathy, cardiovascular diseases and ototoxicity. Only four of our patients developed neutropenic fever after three cycles, recovering uneventfully, and two other patients developed reversible mild peripheral neuropathy. Hypomagnesemia and reduced Inhibitors,research,lifescience,medical glomerular filtration rate were found in

patient #22 following ifosfamide-based salvage regimen. Bleomycin is an important component of the BEP regimen, usually given in 30 units intravenously weekly (days 2, 9, and 16) in three to four cycles, up to Inhibitors,research,lifescience,medical a cumulative dose of 270–360 units. Such cumulative doses might cause the feared and sometimes fatal bleomycin-induced pneumonitis (BIP). Three of the patients (Table 3, patients #4, #6, and #20) Inhibitors,research,lifescience,medical developed BIP. All three patients exhibited the classic clinical signs, such as severe non-productive cough, exertional dyspnea and fever,

and the characteristic radiological signs of bilateral bi-basilar selleck chemical infiltrates progressing into airspace consolidation and ground-glass Inhibitors,research,lifescience,medical opacities. All three patients responded promptly to high-dose steroids and broad-spectrum antibiotics. Generally, BIP may occur in up to 46% of patients treated with bleomycin-containing regimens, with mortality up to 3%.10 A central pathological event in the pathogenesis of BIP is endothelial damage of the lung vasculature, mediated through cytokines and free radicals which contribute to endothelial cell damage and to subsequent infiltration of inflammatory cells into the interstitium, activation of fibroblasts and accompanying excess collagen deposition, and the irreversible GPX6 process of fibrosis continuing until respiratory failure.10,11 Diagnosis is based on clinical symptoms, radiography, and pulmonary function tests. In unclear cases bronchoscopy with broncho-alveolar lavage and/or lung biopsy should be done. Un- or undertreated BIP progresses to severe dyspnea at rest, tachypnea, and cyanosis, and radiologically into diffuse and massive interstitial/alveolar infiltrates, lobar consolidation, and diffuse end-stage fibrosis.